Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy
Conditions
Keywords
endometrial cancer, ovarian cancer, breast cancer, uterine sarcoma, uterine endometrioid adenocarcinoma
Brief summary
This is a multi-center, open-label, randomized, parallel group two-stage phase 1 study with a phase 2 expansion component in pts with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma. Stage 1: Six dose cohorts, 5 using the extended release tablet (ER) formulation (10 mg BID, 20 mg BID, 30 mg BID, 40 mg BID, 50 mg BID) and 1 using the immediate-release (IR) tablet formulation 100 mg QD will be randomized in parallel. After enrollment of 36 patients in Stage 1, a dose of 50 mg BID was determined to be the RP2D. Stage 2: An additional 10 patients with recurrent or metastatic APRpos uterine endometrioid adenocarcinoma (Stage 2a) will be enrolled at the RP2D. Based on the response in Stage 2a, the cohort will be further expanded by up to 19 more patients to a total of 29 patients to confirm the efficacy and safety profile of onapristone in this selected patient population (Stage 2b).
Interventions
DRUGonapristone
Sponsors
Arno Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Post- menopausal female patients, 18 years of age or greater. 2. In Stage 1, recurrent or metastatic PR-expressing cancer that has the potential to benefit from an anti-progestin treatment including but not limited to endometrial cancer, ovarian, or breast cancer or uterine sarcoma. In Stage 2, recurrent or metastatic PR-expression uterine endometrioid adenocarcinoma that is determined to be APRpos. 3. Patients who have metastatic or recurrent disease after previous surgery, radiation therapy, and/or chemotherapy are eligible. In Stage 1, no restriction is placed on the number of prior therapies. In Stage 2, patients may have 0 or 1 prior chemotherapy treatments for adjuvant or metastatic disease and no prior endocrine therapies. 4. In Stage 1, evaluable disease per RECIST 1.1. In Stage 2, measurable disease. 5. Appropriate archival OR current tissue blocks or biopsy specimens to determine ER/PR and APR status. 6. Signed, written informed consent must be obtained and documented according to ICH-GCP, the local regulatory requirements, and local data protection laws prior to study-specific screening procedures. 7. ECOG performance status 0-1. 8. Health care coverage.
Exclusion criteria
1. Calculated creatinine clearance of \<60 mL/min in Stage 1 and \<40 mL/min in Stage 2 2. Patients with any other prior malignancy are not allowed except for the following: * Adequately treated basal cell or squamous cell skin cancer * In situ cervical cancer * Adequately treated Stage I or II cancer from which the patient is currently in complete remission or other cancer from which the patient has been disease-free for 2 years 3. Body mass index (BMI) \<18.5 or \>35 kg/m2. 4. On ECG a QTc(F) interval \>480 msec or any clinically significant cardiac rhythm abnormalities. 5. Liver function tests documented within the screening period and on day -1 of treatment period: * Total bilirubin \> ULN (except in patients diagnosed with Gilbert's disease). * Alkaline phosphatase \> UNL or \> 2.5 x UNL in case of liver metastases, or \> 5 x UNL in case of bone metastases. * ALT/AST \> UNL or \> 2.5 x UNL in case of liver metastases. 6. Known positive virology/serology for human immunodeficiency virus (HIV)-1, HIV-2, hepatitis B (surface antigen), or hepatitis C. 7. Chronic inflammatory liver condition. 8. Chronic adrenal failure or is receiving concurrent long-term corticosteroid therapy. 9. History or clinical evidence of any surgical or medical condition which the investigator judges as likely to interfere with the results of the study or pose an additional risk in participating. 10. Used any prescription medication during the prior 1 month that the investigator judges is likely to interfere with the study or to pose an additional risk to the patient in participating. 11. Received an investigational product or been treated with an investigational device within 30 days prior to first drug administration, or plans to start any other investigational product or device study within 30 days after last drug administration. 12. Received prior systemic anticancer treatment (chemotherapy, targeted therapies including kinase inhibitors, antibodies, etc) less than 5 half-lives before the first dose of study drug or radiotherapy within 30 days; toxicity of the anticancer treatment must have recovered to grade 1 or less. 13. Current progestin-based hormone replacement therapy. 14. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to swallow pills. 15. Has a mental incapacity or language barriers precluding adequate understanding, co-operation, and compliance with the study requirements. 16. Is, in the judgment of the investigator, unable or unwilling to comply with the requirements of the study. 17. Uncontrolled brain metastases or treatment by neurosurgical resection or brain biopsy within 4 weeks prior to Day 1. 18. For Stage 2 only, mixed histology i.e. patients with \>10% non-endometrioid malignant cells in provided histopathology samples.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stage 1: RP2D of a single agent extended-release tablet formulation of oral onapristone for future clinical development. | Baseline to 57 days post-first dose |
| Stage 2: ORR using RECIST 1.1 in 10-29 patients with recurrent or metastatic uterine endometrioid adenocarcinoma that is APRpos, and to determine the relationship between APR status and onapristone anti-tumor activity. | Baseline to 30 Days after last dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety and tolerability of extended-release onapristone tablets BID and of immediate-release onapristone tablets QD | Baseline to 30 Days after last dose | Safety will be assessed by physical exam, vital signs, monitoring of adverse events, changes in ECG, and other clinical laboratory values |
| Comparison of safety of extended-release BID vs. immediate release QD schedules | Baseline to 30 Days after last dose | Safety will be assessed by physical exam, vital signs, monitoring of adverse events, changes in ECG, and other clinical laboratory values |
| Anti-tumor activity based on tumor assessments (RECIST 1.1) and dates of progression | Baseline to 30 Days after last dose | — |
| PK of onapristone, mono-demethylated onapristone and other metabolites in plasma and urine | Baseline to 30 Days after last dose | AUC, Cmax, Tmax, t1/2 |
Countries
France
Contacts
Primary ContactAlice S Bexon, MD
Outcome results
None listed